The approval marks a significant milestone for the American pharmaceutical company in the field of UC, following the approval by the FDA in October 2023 and the EMA approval in February 2024.
Genmab on Wednesday announced that it will acquire the privately owned biotech ProfoundBio for $1.8 billion in cash. The deal is meant to help the Danish pharma deepen its cancer pipeline with next-generation antibody-drug conjugate therapies.
Multiple doses of Eli Lilly’s top-selling diabetes medication Mounjaro (tirzepatide) will be in short supply through April 2024, according to the FDA’s database for drug shortages and discontinuations.
Acorda Therapeutics on Monday announced that it has voluntarily filed for bankruptcy and is seeking Chapter 11 protections to facilitate the orderly transfer of its assets and the winding down of its business operations.
Kintara Therapeutics Inc. and TuHURA Biosciences Inc. announced that they have entered into a definitive agreement for an all-stock transaction forming a company with expertise and resources to advance a risk-diversified late-stage oncology pipeline.
Canada’s largest pharmaceutical company, Apotex Incand Searchlight Pharma Inc., one of Canada’s fastest growing companies, announced that they have reached an agreement whereby Apotex will acquire Searchlight.
Eiger BioPharmaceuticals on Monday announced that it has voluntarily filed for bankruptcy and has kicked off the process of selling its assets and winding down the company’s operations.
Last week, Swiss contract manufacturer Lonza announced it was paying $1.2 billion to buy a Roche manufacturing facility in Vacaville, California. The deal is meant to boost Lonza’s production of commercial mammalian products, which are made from cells isolated from animal tissues, and to expand its U.S. manufacturing footprint. The acquisition is indicative of the growing reliance of biopharma companies on contract manufacturers for biologics.
According to its SEC filing at the time, Boundless will use the IPO proceeds to fund the development of its extrachromosomal DNA (ecDNA) programs, being developed for cancer indications.
Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products.
